ATE227987T1 - Behandlung von gemütskrankheiten mit funktionellen antagonisten des glycin/nmda- rezeptorkomplexes - Google Patents

Behandlung von gemütskrankheiten mit funktionellen antagonisten des glycin/nmda- rezeptorkomplexes

Info

Publication number
ATE227987T1
ATE227987T1 AT91912311T AT91912311T ATE227987T1 AT E227987 T1 ATE227987 T1 AT E227987T1 AT 91912311 T AT91912311 T AT 91912311T AT 91912311 T AT91912311 T AT 91912311T AT E227987 T1 ATE227987 T1 AT E227987T1
Authority
AT
Austria
Prior art keywords
treatment
receptor complex
glycine
nmda receptor
functional antagonists
Prior art date
Application number
AT91912311T
Other languages
English (en)
Inventor
Ramon Trullas
Phil Skolnick
Original Assignee
Us Secretary United States Dep
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Secretary United States Dep filed Critical Us Secretary United States Dep
Application granted granted Critical
Publication of ATE227987T1 publication Critical patent/ATE227987T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT91912311T 1990-06-18 1991-06-11 Behandlung von gemütskrankheiten mit funktionellen antagonisten des glycin/nmda- rezeptorkomplexes ATE227987T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/541,032 US5086072A (en) 1990-06-18 1990-06-18 Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
PCT/US1991/003972 WO1991019493A1 (en) 1990-06-18 1991-06-11 Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex

Publications (1)

Publication Number Publication Date
ATE227987T1 true ATE227987T1 (de) 2002-12-15

Family

ID=24157917

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91912311T ATE227987T1 (de) 1990-06-18 1991-06-11 Behandlung von gemütskrankheiten mit funktionellen antagonisten des glycin/nmda- rezeptorkomplexes

Country Status (8)

Country Link
US (1) US5086072A (de)
EP (1) EP0533832B1 (de)
JP (1) JP2609968B2 (de)
AT (1) ATE227987T1 (de)
AU (1) AU651125B2 (de)
CA (1) CA2085135C (de)
DE (1) DE69133156T2 (de)
WO (1) WO1991019493A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017957A (en) * 1989-08-08 2000-01-25 The United States Of America As Represented By The Department Of Health And Human Services Partial agonists of the strychnine insensitive glycine modulatory site of the N-methyl-D-aspartate receptor complex as neuropsychopharmacological agents
US5854217A (en) 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
US5428069A (en) * 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
US5523323A (en) * 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
US6355681B2 (en) * 1995-12-07 2002-03-12 Glytech, Inc. Glycine substitutes and precursors for treating a psychosis
PT871440E (pt) * 1995-12-07 2006-07-31 Daniel C Javitt Tratamento de sintomas negativos e cognitivos de esquizofrenia com antagonistas da captacao de glicina
US6361957B1 (en) * 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
EP0964691A4 (de) 1996-07-22 2002-10-30 Cognetix Inc Verwendung von conantokine
US6277825B1 (en) 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
US6515103B1 (en) 1996-07-22 2003-02-04 University Of Utah Research Foundation Conantokins
US6391922B1 (en) 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
US20060167114A1 (en) * 1998-03-09 2006-07-27 Louis Shuster Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
US6242456B1 (en) 1998-03-09 2001-06-05 Trustees Of Tufts College Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
US20070197651A1 (en) * 1998-03-09 2007-08-23 Tufts University Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
DE1073432T1 (de) * 1998-04-14 2002-02-07 The General Hospital Corp., Boston Verwendung von glycinrezeptoragonisten und glycinaufnahmeinhibitoren zur behandlung neuropsychiatrischer beschwerden
US6399574B1 (en) 2000-03-22 2002-06-04 University Of Utah Research Foundation Use of conantokins
JP2002140219A (ja) * 2000-11-01 2002-05-17 Toshiba Corp ファイル処理方法、ファイル処理装置、ファイル管理用記録媒体
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
AU2002311784B2 (en) * 2001-03-29 2007-11-22 Michael Davis Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
EP1389181A4 (de) 2001-04-02 2005-10-19 Panorama Res Inc Nitroxid- und nitron-antioxidationsmittel als therapeutika
EP2260844A1 (de) 2003-05-27 2010-12-15 Merz Pharma GmbH & Co. KGaA Kombination eines NMDA-Rezeptorantagonisten und eines selektiven Serotonin-Wiederaufnahmeinhibitoren zur Behandlung von Depression und Gemütserkrankungen
EP1660634A4 (de) * 2003-08-08 2009-02-18 Burnham Inst P16-vermittelte regulation von nmda-rezeptoren
UY28650A1 (es) * 2003-12-05 2005-02-28 Forest Laboratories Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta
WO2005065308A2 (en) 2003-12-29 2005-07-21 Jason Mcdevitt Compositions and methods to treat recurrent medical conditions
US20060084659A1 (en) * 2004-10-19 2006-04-20 Michael Davis Augmentation of psychotherapy with cannabinoid reuptake inhibitors
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
US7531572B2 (en) * 2006-07-28 2009-05-12 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use
WO2009128058A1 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
MX2011003015A (es) 2008-09-18 2011-11-18 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
MX365650B (es) 2009-12-02 2019-06-10 Adamas Pharmaceuticals Inc Composiciones de amantadina y metodos para su uso.
CN105037492A (zh) 2010-02-11 2015-11-11 西北大学 二级结构稳定化的nmda受体调节剂及其用途
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
JP2012158527A (ja) * 2011-01-31 2012-08-23 Mitsubishi Gas Chemical Co Inc うつ予防
EP2931291B1 (de) 2012-12-11 2021-10-20 The McLean Hospital Corporation Xenonbehandlung als zusatz für psychotherapie bei psychiatrischen erkrankungen
EP4385563A3 (de) 2013-01-22 2024-08-21 Vistagen Therapeutics, Inc. Dosierungsformen und therapeutische verwendungen von l-4-chlorkynurenin
KR20150110586A (ko) 2013-01-29 2015-10-02 노렉스, 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
EA032649B1 (ru) 2013-01-29 2019-06-28 Аптиникс Инк. Спиролактамные модуляторы nmda-рецептора и их применение
SG11201505862TA (en) 2013-01-29 2015-08-28 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
SG11201505942YA (en) 2013-01-29 2015-08-28 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
KR20150110787A (ko) 2013-01-29 2015-10-02 노렉스, 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
BR112018073663A2 (pt) 2016-05-19 2019-04-30 Aptinyx Inc. moduladores de receptores nmda spiro-lactâmicos e seus usos
MX385336B (es) 2016-08-01 2025-03-18 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos.
JP2019527232A (ja) 2016-08-01 2019-09-26 アプティニックス インコーポレイテッド スピロ−ラクタムｎｍｄａ修飾因子及びこれを用いた方法
SG10202101055VA (en) 2016-08-01 2021-03-30 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
EP3490994B8 (de) 2016-08-01 2024-03-13 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam und bis-spiro-lactam nmda rezeptor modulatoren und deren verwendung
WO2018026782A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN112204031B (zh) 2018-01-31 2024-05-24 元羿生物科技(香港)有限公司 螺-内酰胺nmda受体调节剂及其用途
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE882361R (fr) * 1980-03-21 1980-09-22 Merck & Co Inc PROCEDE DE PREPARATION DE 10,11-DIHYDRO-5H-DIBENZO (a,d) CYCLOHEPTENE-5,10-IMINES SUBSTITUEES EN POSITION 5
GB8625941D0 (en) * 1986-10-30 1986-12-03 Sandoz Ltd Substituted alpha-amino acids
GB8703749D0 (en) * 1987-02-18 1987-03-25 Sandoz Ltd Piperazinecarboxylic acid
US6017957A (en) * 1989-08-08 2000-01-25 The United States Of America As Represented By The Department Of Health And Human Services Partial agonists of the strychnine insensitive glycine modulatory site of the N-methyl-D-aspartate receptor complex as neuropsychopharmacological agents

Also Published As

Publication number Publication date
WO1991019493A1 (en) 1991-12-26
CA2085135A1 (en) 1991-12-19
EP0533832A4 (en) 1993-04-28
AU651125B2 (en) 1994-07-14
DE69133156D1 (de) 2003-01-02
US5086072A (en) 1992-02-04
DE69133156T2 (de) 2003-03-27
AU8208491A (en) 1992-01-07
EP0533832A1 (de) 1993-03-31
JP2609968B2 (ja) 1997-05-14
CA2085135C (en) 1997-02-25
JPH06501454A (ja) 1994-02-17
EP0533832B1 (de) 2002-11-20

Similar Documents

Publication Publication Date Title
ATE227987T1 (de) Behandlung von gemütskrankheiten mit funktionellen antagonisten des glycin/nmda- rezeptorkomplexes
WO1990014067A3 (en) Methods for treating anxiety with sigma receptor ligands
LU91271I2 (fr) Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI)
DE69129302D1 (de) Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen
DE69532482D1 (de) Kombinationspräparat zur behandlung der parkinsonschen krankheit, das selektive nmda-antagonisten enthält
DE69329503D1 (de) Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
NZ299859A (en) Oxazolidine and morpholine derivatives; medicaments for treatment of central nervous system diseases
EA199700116A1 (ru) Трициклические бензазепины как антагонисты вазопрессина, способ их получения, фармкомпозиция на их основе и способ лечения
EA200300528A1 (ru) 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
DE69720745D1 (de) Therapeutische kombinationen von rar-antagonisten und rxr-agonisten
DE69625157D1 (de) Behandlung des typ ii-deabetes mellitus mit amylinagonisten
NO960630D0 (no) Heterocykler anvendelige som neurokinin antagonister
EA199700111A1 (ru) Трициклические бензазепиновые антагонисты вазопрессина
NO944578L (no) Eksitatoriske aminosyre reseptor antagonister
EA200300716A1 (ru) Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
FI903827A0 (fi) Foerfarande foer reducering av immunoglobulin e-responser.
ATE185969T1 (de) Potenzierung von nmda-antagonisten
EA199800864A1 (ru) Способ лечения при боли, вызванной мигренью
EA200000693A1 (ru) Антагонисты хемокинного рецептора и способы их применения
AU655958B2 (en) Use of quisqualate-receptor antagonists for treating Parkinson's disease
GR3034035T3 (en) A process for the preparation of factor ix from biological sources
ATE167398T1 (de) Behandlungsverfahren für therapiewiderstehende schizophrenie mit amperozide
DE59006159D1 (de) Verwendung von macrolactonen als antiallergica.
MY106163A (en) Bcrf1 antagonists for treating epstein-barr virus infections.
ES8300477A1 (es) Procedimiento para la preparacion de una composicion para el tratamiento del cancer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties